Long Focus Capital Management, LLC Adaptimmune Therapeutics PLC Transaction History
Long Focus Capital Management, LLC
- $2.49 Billion
- Q2 2024
A detailed history of Long Focus Capital Management, LLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Long Focus Capital Management, LLC holds 12,346,417 shares of ADAP stock, worth $11.7 Million. This represents 0.49% of its overall portfolio holdings.
Number of Shares
12,346,417
Previous 10,684,233
15.56%
Holding current value
$11.7 Million
Previous $16.9 Million
28.33%
% of portfolio
0.49%
Previous 0.91%
Shares
12 transactions
Others Institutions Holding ADAP
# of Institutions
81Shares Held
152MCall Options Held
78.5KPut Options Held
36.5K-
Matrix Capital Management Company, LP Waltham, MA39MShares$37 Million0.29% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$26 Million0.95% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$16.2 Million1.58% of portfolio
-
Baillie Gifford & CO15.1MShares$14.4 Million0.01% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA10.5MShares$9.99 Million0.53% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $155M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...